The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.
The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.
The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.
Due to a ransom cyberattack on its information technology systems, the firm reported full revenue but only preliminary earnings estimates.
The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.
